### Analysis

Johnson & Johnson's Q2 2016 earnings call revealed strong performance across all segments, with sales and earnings exceeding expectations. The company reported $18.5 billion in sales, up 3.9% year-over-year, and net earnings of $4 billion, up 1.1% year-over-year. The company's guidance for 2016 was also increased, with sales expected to grow by 3% to 4% and adjusted EPS expected to grow by 7.4% to 9%.

Key highlights from the call include:

1. **Operational Growth**: The company reported strong operational growth, with underlying operational sales growth of 5.3% and adjusted net earnings per share growth of 1.8%. This was driven by strong performance in the Pharmaceuticals and Medical Devices segments, as well as improvements in the Consumer segment.

2. **Pharmaceuticals**: The Pharmaceuticals segment reported sales of $8.7 billion, up 9.7% year-over-year. This was driven by strong sales of new products and core growth products, as well as positive gross-to-net adjustments. The company also reported strong growth in immunology products, oncology products, and cardiovascular metabolic products.

3. **Medical Devices**: The Medical Devices segment reported sales of $6.4 billion, up 1.8% year-over-year. This was driven by strong growth in Advanced Surgery, Electrophysiology, Orthopedics, and Vision Care. The company also reported strong results for the U.S. Orthopedics business, with growth driven by market growth and the success of product launches.

4. **Consumer**: The Consumer segment reported sales of $3.4 billion, up 1.5% year-over-year. This was driven by strong growth in skin care, OTC, and oral care. The company also reported strong growth in anti-smoking aids, children's analgesics, and digestive health products.

5. **Guidance**: The company increased its guidance for 2016, with sales expected to grow by 3% to 4% and adjusted EPS expected to grow by 7.4% to 9%. The company also reported strong progress towards its goal of a 200 basis point increase in pre-tax operating margin, with the margin increasing by 180 basis points in the first half of the year.

### Conclusion

Johnson & Johnson's strong performance in Q2 2016, as well as its increased guidance for 2016, suggests that the company is well-positioned to continue its growth trajectory. The company's strong operational growth, driven by its diverse portfolio of products and services, as well as its focus on innovation and strategic growth, should continue to drive its success in the coming quarters. Therefore, the stock is likely to experience a positive impact in the short term.

**Rating: 2**